ChloroquineV1, PascalFrancis, Curation, bibRecord, 000050

Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey

Identifieur interne : 000050 ( PascalFrancis/Curation ); précédent : 000049; suivant : 000051

Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey

Auteurs : Elizabeth Stringer [Canada, États-Unis, Royaume-Uni] ; John Bohnsack ; Suzanne L. Bowyer ; Thomas A. Griffin ; Adam M. Huber ; Bianca Lang ; Carol B. Lindsley ; Sylvia Ota ; Clarissa Pilkington ; Ann M. Reed ; Rosie Scuccimarri ; Brian M. Feldman

Source :

Journal of rheumatology [ 0315-162X ] ; 2010.

RBID : Pascal:10-0446161

Descripteurs français

Pascal (Inist)
- Traitement, Voie abord, Dermatomyosite, Adolescent, Amérique du Nord, Enfant, Arthrite, Rhumatologie, Enquête, Pédiatrie, Myosite.
Wicri :
- topic : Enfant, Pédiatrie.

English descriptors

KwdEn :
- Adolescent, Arthritis, Child, Dermatomyositis, Myositis, North America, Pediatrics, Rheumatology, Surgical approach, Survey, Treatment.

Abstract

Objective. There are a number of different approaches to the initial treatment of juvenile dermatomyositis (JDM). We assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. Methods. A survey describing clinical cases of JDM was sent to pediatric rheumatologists. The cases described children with varying severity of typical disease, disease with atypical features, or refractory disease. Three open-ended questions were asked following each case: (1) What additional investigations would you order; (2) What medicine(s) would you start (dose, route, frequency, adjustment over time); and (3) What nonmedication treatment(s) would you start. Results. The response rate was 84% (141/167). For typical cases of JDM, regardless of severity, almost all respondents used corticosteroids and another medication, methotrexate (MTX) being the most commonly used. The route and pattern of corticosteroid administration was variable. Intravenous immunoglobulin (IVIG) was used more frequently for more severe disease, for refractory disease, and for prominent cutaneous disease. Hydroxychloroquine was often used in milder cases and cases principally characterized by rash. Cyclophosphamide was reserved for ulcerative disease and JDM complicated by lung disease. Conclusion. For the majority of North American pediatric rheumatologists, corticosteroids and MTX appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine.

A01	`01`	`1`		`@0 0315-162X`
A02	`01`			`@0 JRHUA9`
A03		`1`		`@0 J. rheumatol.`
A05				`@2 37`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey`
A11	`01`	`1`		`@1 STRINGER (Elizabeth)`
A11	`02`	`1`		`@1 BOHNSACK (John)`
A11	`03`	`1`		`@1 BOWYER (Suzanne L.)`
A11	`04`	`1`		`@1 GRIFFIN (Thomas A.)`
A11	`05`	`1`		`@1 HUBER (Adam M.)`
A11	`06`	`1`		`@1 LANG (Bianca)`
A11	`07`	`1`		`@1 LINDSLEY (Carol B.)`
A11	`08`	`1`		`@1 OTA (Sylvia)`
A11	`09`	`1`		`@1 PILKINGTON (Clarissa)`
A11	`10`	`1`		`@1 REED (Ann M.)`
A11	`11`	`1`		`@1 SCUCCIMARRI (Rosie)`
A11	`12`	`1`		`@1 FELDMAN (Brian M.)`
A14	`01`			`@1 IWK Health Centre @2 Halifax, Nova Scotia @3 CAN`
A14	`02`			`@1 University of Utah School of Medicine @2 Salt Lake City, Utah @3 USA`
A14	`03`			`@1 Indiana University School of Medicine @2 Indianapolis, Indiana @3 USA`
A14	`04`			`@1 Cincinnati Children's Hospital @2 Cincinnati, Ohio @3 USA`
A14	`05`			`@1 University of Kansas Medical Center @2 Kansas City, Kansas @3 USA`
A14	`06`			`@1 The Hospital for Sick Children @2 Toronto, Ontario @3 CAN`
A14	`07`			`@1 Great Ormond Street Hospital for Children @2 London @3 GBR`
A14	`08`			`@1 Mayo Clinic @2 Rochester, Minnesota @3 USA`
A14	`09`			`@1 Montreal Children's Hospital @2 Montreal, Quebec @3 CAN`
A20				`@1 1953-1961`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16024 @5 354000194840140270`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 43 ref.`
A47	`01`	`1`		`@0 10-0446161`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of rheumatology`
A66	`01`			`@0 CAN`
C01	`01`		`ENG`	@0 Objective. There are a number of different approaches to the initial treatment of juvenile dermatomyositis (JDM). We assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. Methods. A survey describing clinical cases of JDM was sent to pediatric rheumatologists. The cases described children with varying severity of typical disease, disease with atypical features, or refractory disease. Three open-ended questions were asked following each case: (1) What additional investigations would you order; (2) What medicine(s) would you start (dose, route, frequency, adjustment over time); and (3) What nonmedication treatment(s) would you start. Results. The response rate was 84% (141/167). For typical cases of JDM, regardless of severity, almost all respondents used corticosteroids and another medication, methotrexate (MTX) being the most commonly used. The route and pattern of corticosteroid administration was variable. Intravenous immunoglobulin (IVIG) was used more frequently for more severe disease, for refractory disease, and for prominent cutaneous disease. Hydroxychloroquine was often used in milder cases and cases principally characterized by rash. Cyclophosphamide was reserved for ulcerative disease and JDM complicated by lung disease. Conclusion. For the majority of North American pediatric rheumatologists, corticosteroids and MTX appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine.
C02	`01`	`X`		`@0 002B15I`
C02	`02`	`X`		`@0 002B07`
C02	`03`	`X`		`@0 002B17H`
C03	`01`	`X`	`FRE`	`@0 Traitement @5 07`
C03	`01`	`X`	`ENG`	`@0 Treatment @5 07`
C03	`01`	`X`	`SPA`	`@0 Tratamiento @5 07`
C03	`02`	`X`	`FRE`	`@0 Voie abord @5 08`
C03	`02`	`X`	`ENG`	`@0 Surgical approach @5 08`
C03	`02`	`X`	`SPA`	`@0 Vía abordaje @5 08`
C03	`03`	`X`	`FRE`	`@0 Dermatomyosite @5 09`
C03	`03`	`X`	`ENG`	`@0 Dermatomyositis @5 09`
C03	`03`	`X`	`SPA`	`@0 Dermatomiositis @5 09`
C03	`04`	`X`	`FRE`	`@0 Adolescent @5 10`
C03	`04`	`X`	`ENG`	`@0 Adolescent @5 10`
C03	`04`	`X`	`SPA`	`@0 Adolescente @5 10`
C03	`05`	`X`	`FRE`	`@0 Amérique du Nord @2 NG @5 13`
C03	`05`	`X`	`ENG`	`@0 North America @2 NG @5 13`
C03	`05`	`X`	`SPA`	`@0 America del norte @2 NG @5 13`
C03	`06`	`X`	`FRE`	`@0 Enfant @5 14`
C03	`06`	`X`	`ENG`	`@0 Child @5 14`
C03	`06`	`X`	`SPA`	`@0 Niño @5 14`
C03	`07`	`X`	`FRE`	`@0 Arthrite @5 15`
C03	`07`	`X`	`ENG`	`@0 Arthritis @5 15`
C03	`07`	`X`	`SPA`	`@0 Artritis @5 15`
C03	`08`	`X`	`FRE`	`@0 Rhumatologie @5 16`
C03	`08`	`X`	`ENG`	`@0 Rheumatology @5 16`
C03	`08`	`X`	`SPA`	`@0 Reumatología @5 16`
C03	`09`	`X`	`FRE`	`@0 Enquête @5 17`
C03	`09`	`X`	`ENG`	`@0 Survey @5 17`
C03	`09`	`X`	`SPA`	`@0 Encuesta @5 17`
C03	`10`	`X`	`FRE`	`@0 Pédiatrie @5 18`
C03	`10`	`X`	`ENG`	`@0 Pediatrics @5 18`
C03	`10`	`X`	`SPA`	`@0 Pediatría @5 18`
C03	`11`	`X`	`FRE`	`@0 Myosite @5 19`
C03	`11`	`X`	`ENG`	`@0 Myositis @5 19`
C03	`11`	`X`	`SPA`	`@0 Miositis @5 19`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Amérique @2 NG`
C07	`02`	`X`	`ENG`	`@0 America @2 NG`
C07	`02`	`X`	`SPA`	`@0 America @2 NG`
C07	`03`	`X`	`FRE`	`@0 Maladie autoimmune @5 37`
C07	`03`	`X`	`ENG`	`@0 Autoimmune disease @5 37`
C07	`03`	`X`	`SPA`	`@0 Enfermedad autoinmune @5 37`
C07	`04`	`X`	`FRE`	`@0 Maladie de système @5 38`
C07	`04`	`X`	`ENG`	`@0 Systemic disease @5 38`
C07	`04`	`X`	`SPA`	`@0 Enfermedad sistémica @5 38`
C07	`05`	`X`	`FRE`	`@0 Pathologie du muscle strié @5 39`
C07	`05`	`X`	`ENG`	`@0 Striated muscle disease @5 39`
C07	`05`	`X`	`SPA`	`@0 Músculo estriado patología @5 39`
C07	`06`	`X`	`FRE`	`@0 Pathologie de la peau @5 40`
C07	`06`	`X`	`ENG`	`@0 Skin disease @5 40`
C07	`06`	`X`	`SPA`	`@0 Piel patología @5 40`
C07	`07`	`X`	`FRE`	`@0 Pathologie du tissu conjonctif @5 41`
C07	`07`	`X`	`ENG`	`@0 Connective tissue disease @5 41`
C07	`07`	`X`	`SPA`	`@0 Tejido conjuntivo patología @5 41`
C07	`08`	`X`	`FRE`	`@0 Immunopathologie @5 42`
C07	`08`	`X`	`ENG`	`@0 Immunopathology @5 42`
C07	`08`	`X`	`SPA`	`@0 Inmunopatología @5 42`
C07	`09`	`X`	`FRE`	`@0 Pathologie du système ostéoarticulaire @5 43`
C07	`09`	`X`	`ENG`	`@0 Diseases of the osteoarticular system @5 43`
C07	`09`	`X`	`SPA`	`@0 Sistema osteoarticular patología @5 43`
N21				`@1 291`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000016

Links to Exploration step

Pascal:10-0446161

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey</title>
<author><name sortKey="Stringer, Elizabeth" sort="Stringer, Elizabeth" uniqKey="Stringer E" first="Elizabeth" last="Stringer">Elizabeth Stringer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IWK Health Centre</s1>
<s2>Halifax, Nova Scotia</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Utah School of Medicine</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Indiana University School of Medicine</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Cincinnati Children's Hospital</s1>
<s2>Cincinnati, Ohio</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>The Hospital for Sick Children</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Great Ormond Street Hospital for Children</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Montreal Children's Hospital</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Bohnsack, John" sort="Bohnsack, John" uniqKey="Bohnsack J" first="John" last="Bohnsack">John Bohnsack</name>
</author>
<author><name sortKey="Bowyer, Suzanne L" sort="Bowyer, Suzanne L" uniqKey="Bowyer S" first="Suzanne L." last="Bowyer">Suzanne L. Bowyer</name>
</author>
<author><name sortKey="Griffin, Thomas A" sort="Griffin, Thomas A" uniqKey="Griffin T" first="Thomas A." last="Griffin">Thomas A. Griffin</name>
</author>
<author><name sortKey="Huber, Adam M" sort="Huber, Adam M" uniqKey="Huber A" first="Adam M." last="Huber">Adam M. Huber</name>
</author>
<author><name sortKey="Lang, Bianca" sort="Lang, Bianca" uniqKey="Lang B" first="Bianca" last="Lang">Bianca Lang</name>
</author>
<author><name sortKey="Lindsley, Carol B" sort="Lindsley, Carol B" uniqKey="Lindsley C" first="Carol B." last="Lindsley">Carol B. Lindsley</name>
</author>
<author><name sortKey="Ota, Sylvia" sort="Ota, Sylvia" uniqKey="Ota S" first="Sylvia" last="Ota">Sylvia Ota</name>
</author>
<author><name sortKey="Pilkington, Clarissa" sort="Pilkington, Clarissa" uniqKey="Pilkington C" first="Clarissa" last="Pilkington">Clarissa Pilkington</name>
</author>
<author><name sortKey="Reed, Ann M" sort="Reed, Ann M" uniqKey="Reed A" first="Ann M." last="Reed">Ann M. Reed</name>
</author>
<author><name sortKey="Scuccimarri, Rosie" sort="Scuccimarri, Rosie" uniqKey="Scuccimarri R" first="Rosie" last="Scuccimarri">Rosie Scuccimarri</name>
</author>
<author><name sortKey="Feldman, Brian M" sort="Feldman, Brian M" uniqKey="Feldman B" first="Brian M." last="Feldman">Brian M. Feldman</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0446161</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0446161 INIST</idno>
<idno type="RBID">Pascal:10-0446161</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000016</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000050</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey</title>
<author><name sortKey="Stringer, Elizabeth" sort="Stringer, Elizabeth" uniqKey="Stringer E" first="Elizabeth" last="Stringer">Elizabeth Stringer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IWK Health Centre</s1>
<s2>Halifax, Nova Scotia</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Utah School of Medicine</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Indiana University School of Medicine</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Cincinnati Children's Hospital</s1>
<s2>Cincinnati, Ohio</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>The Hospital for Sick Children</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Great Ormond Street Hospital for Children</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Montreal Children's Hospital</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Bohnsack, John" sort="Bohnsack, John" uniqKey="Bohnsack J" first="John" last="Bohnsack">John Bohnsack</name>
</author>
<author><name sortKey="Bowyer, Suzanne L" sort="Bowyer, Suzanne L" uniqKey="Bowyer S" first="Suzanne L." last="Bowyer">Suzanne L. Bowyer</name>
</author>
<author><name sortKey="Griffin, Thomas A" sort="Griffin, Thomas A" uniqKey="Griffin T" first="Thomas A." last="Griffin">Thomas A. Griffin</name>
</author>
<author><name sortKey="Huber, Adam M" sort="Huber, Adam M" uniqKey="Huber A" first="Adam M." last="Huber">Adam M. Huber</name>
</author>
<author><name sortKey="Lang, Bianca" sort="Lang, Bianca" uniqKey="Lang B" first="Bianca" last="Lang">Bianca Lang</name>
</author>
<author><name sortKey="Lindsley, Carol B" sort="Lindsley, Carol B" uniqKey="Lindsley C" first="Carol B." last="Lindsley">Carol B. Lindsley</name>
</author>
<author><name sortKey="Ota, Sylvia" sort="Ota, Sylvia" uniqKey="Ota S" first="Sylvia" last="Ota">Sylvia Ota</name>
</author>
<author><name sortKey="Pilkington, Clarissa" sort="Pilkington, Clarissa" uniqKey="Pilkington C" first="Clarissa" last="Pilkington">Clarissa Pilkington</name>
</author>
<author><name sortKey="Reed, Ann M" sort="Reed, Ann M" uniqKey="Reed A" first="Ann M." last="Reed">Ann M. Reed</name>
</author>
<author><name sortKey="Scuccimarri, Rosie" sort="Scuccimarri, Rosie" uniqKey="Scuccimarri R" first="Rosie" last="Scuccimarri">Rosie Scuccimarri</name>
</author>
<author><name sortKey="Feldman, Brian M" sort="Feldman, Brian M" uniqKey="Feldman B" first="Brian M." last="Feldman">Brian M. Feldman</name>
</author>
</analytic>
<series><title level="j" type="main">Journal of rheumatology</title>
<title level="j" type="abbreviated">J. rheumatol.</title>
<idno type="ISSN">0315-162X</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of rheumatology</title>
<title level="j" type="abbreviated">J. rheumatol.</title>
<idno type="ISSN">0315-162X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Arthritis</term>
<term>Child</term>
<term>Dermatomyositis</term>
<term>Myositis</term>
<term>North America</term>
<term>Pediatrics</term>
<term>Rheumatology</term>
<term>Surgical approach</term>
<term>Survey</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Traitement</term>
<term>Voie abord</term>
<term>Dermatomyosite</term>
<term>Adolescent</term>
<term>Amérique du Nord</term>
<term>Enfant</term>
<term>Arthrite</term>
<term>Rhumatologie</term>
<term>Enquête</term>
<term>Pédiatrie</term>
<term>Myosite</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Enfant</term>
<term>Pédiatrie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective. There are a number of different approaches to the initial treatment of juvenile dermatomyositis (JDM). We assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. Methods. A survey describing clinical cases of JDM was sent to pediatric rheumatologists. The cases described children with varying severity of typical disease, disease with atypical features, or refractory disease. Three open-ended questions were asked following each case: (1) What additional investigations would you order; (2) What medicine(s) would you start (dose, route, frequency, adjustment over time); and (3) What nonmedication treatment(s) would you start. Results. The response rate was 84% (141/167). For typical cases of JDM, regardless of severity, almost all respondents used corticosteroids and another medication, methotrexate (MTX) being the most commonly used. The route and pattern of corticosteroid administration was variable. Intravenous immunoglobulin (IVIG) was used more frequently for more severe disease, for refractory disease, and for prominent cutaneous disease. Hydroxychloroquine was often used in milder cases and cases principally characterized by rash. Cyclophosphamide was reserved for ulcerative disease and JDM complicated by lung disease. Conclusion. For the majority of North American pediatric rheumatologists, corticosteroids and MTX appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0315-162X</s0>
</fA01>
<fA02 i1="01"><s0>JRHUA9</s0>
</fA02>
<fA03 i2="1"><s0>J. rheumatol.</s0>
</fA03>
<fA05><s2>37</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>STRINGER (Elizabeth)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BOHNSACK (John)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BOWYER (Suzanne L.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GRIFFIN (Thomas A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HUBER (Adam M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LANG (Bianca)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LINDSLEY (Carol B.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>OTA (Sylvia)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>PILKINGTON (Clarissa)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>REED (Ann M.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>SCUCCIMARRI (Rosie)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>FELDMAN (Brian M.)</s1>
</fA11>
<fA14 i1="01"><s1>IWK Health Centre</s1>
<s2>Halifax, Nova Scotia</s2>
<s3>CAN</s3>
</fA14>
<fA14 i1="02"><s1>University of Utah School of Medicine</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="03"><s1>Indiana University School of Medicine</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="04"><s1>Cincinnati Children's Hospital</s1>
<s2>Cincinnati, Ohio</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="05"><s1>University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="06"><s1>The Hospital for Sick Children</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
</fA14>
<fA14 i1="07"><s1>Great Ormond Street Hospital for Children</s1>
<s2>London</s2>
<s3>GBR</s3>
</fA14>
<fA14 i1="08"><s1>Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="09"><s1>Montreal Children's Hospital</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
</fA14>
<fA20><s1>1953-1961</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16024</s2>
<s5>354000194840140270</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>43 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0446161</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of rheumatology</s0>
</fA64>
<fA66 i1="01"><s0>CAN</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective. There are a number of different approaches to the initial treatment of juvenile dermatomyositis (JDM). We assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. Methods. A survey describing clinical cases of JDM was sent to pediatric rheumatologists. The cases described children with varying severity of typical disease, disease with atypical features, or refractory disease. Three open-ended questions were asked following each case: (1) What additional investigations would you order; (2) What medicine(s) would you start (dose, route, frequency, adjustment over time); and (3) What nonmedication treatment(s) would you start. Results. The response rate was 84% (141/167). For typical cases of JDM, regardless of severity, almost all respondents used corticosteroids and another medication, methotrexate (MTX) being the most commonly used. The route and pattern of corticosteroid administration was variable. Intravenous immunoglobulin (IVIG) was used more frequently for more severe disease, for refractory disease, and for prominent cutaneous disease. Hydroxychloroquine was often used in milder cases and cases principally characterized by rash. Cyclophosphamide was reserved for ulcerative disease and JDM complicated by lung disease. Conclusion. For the majority of North American pediatric rheumatologists, corticosteroids and MTX appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B15I</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B07</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17H</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Traitement</s0>
<s5>07</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Treatment</s0>
<s5>07</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Voie abord</s0>
<s5>08</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Surgical approach</s0>
<s5>08</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vía abordaje</s0>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Dermatomyosite</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dermatomyositis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Dermatomiositis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Adolescent</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Adolescent</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Adolescente</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Amérique du Nord</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>North America</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>America del norte</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Enfant</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Child</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Niño</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Arthrite</s0>
<s5>15</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Arthritis</s0>
<s5>15</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Artritis</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Rhumatologie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Rheumatology</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Reumatología</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Enquête</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Survey</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Encuesta</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Pédiatrie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Pediatrics</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Pediatría</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Myosite</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Myositis</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Miositis</s0>
<s5>19</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Amérique</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie autoimmune</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Autoimmune disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad autoinmune</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie de système</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Systemic disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad sistémica</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du muscle strié</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de la peau</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Skin disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Piel patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie du  tissu conjonctif</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Connective tissue disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Tejido conjuntivo patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>291</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000050 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000050 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:10-0446161
   |texte=   Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey

Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri